Comment
doi: 10.1016/S2215-0366(23)00180-3.
The use of long-acting injectables in early-phase schizophrenia
Affiliations
- PMID: 37353256
- DOI: 10.1016/S2215-0366(23)00180-3
Item in Clipboard
Comment
The use of long-acting injectables in early-phase schizophrenia
Lancet Psychiatry.
2023 Jul.
No abstract available
Conflict of interest statement
I have participated in research projects funded by grants from Eli Lilly and Janssen-Cilag to my employing institution, I report consulting fees from HLS Therapeutics, Janssen, Orion, and WebMed Global, and honoraria for lectures from Eli Lilly, Evidera, Janssen-Cilag, Lundbeck, Mediuutiset, Otsuka, Sidera, and Sunovion.
Comment in
-
The use of long-acting injectables in early-phase schizophrenia - Authors' reply.Lancet Psychiatry. 2023 Jul;10(7):482-483. doi: 10.1016/S2215-0366(23)00182-7. Lancet Psychiatry. 2023. PMID: 37353257 No abstract available.
Comment on
-
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).Lancet Psychiatry. 2023 Mar;10(3):197-208. doi: 10.1016/S2215-0366(23)00005-6. Epub 2023 Jan 27. Lancet Psychiatry. 2023. PMID: 36716759 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
